Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07303140
Recruiting Observational

Non-invasive Assessment of Liver Fibrosis in a French Cohort of Pediatric Patients With Type III Glycogen Storage Disease: Current State and Perspectives

NCT07303140 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Strasbourg, France
Phase
Observational
Started
2024-10-18
Last updated
2025-12-24

Condition(s) studied

Liver Fibrosis

Study summary

Patients with type III glycogen storage disease (GSDIII) can develop liver fibrosis, which can be complicated by liver failure or even hepatocellular carcinoma. Since the beginning of the 21st century, non-invasive techniques for assessing fibrosis, such as liver elastography, have been developed. These techniques often make it possible to avoid liver biopsies during patient follow-up and have already been validated in the management of several diseases in adults. These techniques are also beginning to be recommended for monitoring certain chronic liver diseases in children.

Eligibility

Sex
ALL
Min age
1 Month
Max age
21 Years
Healthy volunteers
No
Inclusion Criteria: * Minors: from birth to 17 years * Adults: 18 to 21 years * Subjects being monitored for type III glycogen storage disease and having had at least one liver elastography measurement during their follow-up. Exclusion Criteria: \- Patients monitored for type III glycogen storage disease but who had never undergone liver elastography during their follow-up.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Service de pédiatrie 1 - CHU de Strasbourg - France Strasbourg France Recruiting

More University Hospital, Strasbourg, France trials in France

The Health of Women Monitored in the Addiction Department of the Strasbourg University Hospitals Recruiting
Platelet and Autotransfusion Device in Cardiac Surgery Recruiting
Stone Disease of the Urinary Tract in Children Recruiting
Late-term Abortions Between 14 and 16 Weeks of Gestation: Comparison of Hemorrhagic Risks in Surgical vs. Medical Abortions Recruiting
Duration of Therapeutic Anticoagulation in Patients With Pulmonary Embolism Recruiting

Other trials for the same condition

City-Hospital Collaboration for Early Detection of Liver Fibrosis in Primary Care: A Secondary Prevention Project in the Grenoble Health Area Recruiting
Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07303140 on ClinicalTrials.gov ↗ ← All trials in France